Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
Odeyemi, Yewande , Tekin, Aysun , Schanz, Caitlin, Schreier, Diana J., Cole, Kristin, Gajic, Ognjen, Frazee, Erin N. , Odeyemi, Yewande E, Schanz, Caitlin C., Schreier, Diana J , Tekin, Aysun , Cole, Kristin, Gajic, Ognjen

Clinical Infectious Diseases | May 15, 2025 | Volume: 82 | Issue: 4 | Pages: 639-647

10.1093/cid/ciaf252 | PMID 40378193 Get It

Abstract Background Doxycycline is a frequently used alternative treatment for community-acquired pneumonia (CAP) in hospitalized patients; however, the evidence base is limited. We aimed to compare outcomes in CAP patients treated with doxycycline or azithromycin in combination with beta-lactams. Methods We evaluated patients with CAP admitted to Mayo Clinic hospitals from May 2018 to September 2022 and treated with either azithromycin or doxycycline in combination with a beta-lactam. Patients who received both antibiotics or were on either antibiotic as chronic therapy prior to admission were excluded. The primary outcome was mortality. Patients were 1-to-1 matched according to the presence of congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, human immunodeficiency virus infection, recent immunosuppressant use, and pneumonia severity index class. Results Among 8492 patients (5810 for azithromycin, 2682 for doxycycline), 2671 doxycycline-treated patients were matched with azithromycin-treated patients. In-hospital mortality was significantly lower in the azithromycin group than in the doxycycline group (odds ratio, 0.71; 95% confidence interval [CI], .56–.9), as was 90-day mortality (hazard ratio, 0.83; 95% CI, .73–.95). Patients on azithromycin also had significantly more hospital-free days (HFDs) than those on doxycycline (estimate, 1.37; 95% CI, .99–1.74). Conclusions Among hospitalized patients with CAP, azithromycin was associated with lower mortality and more HFDs compared with doxycycline in combination with beta-lactams. Randomized, controlled trials are needed to assess the effectiveness of each regimen and to compare their potential side effects.
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism
Farah, Magdoleen H. , Hegazi, Moustafa , Abusalih, Mohamed , Saadi, Samer , Al-Kordi, Mohammad, Elsheikh, Arwa Mahmoud, Hassett, Leslie, Bancos, Irina , Murad, M Hassan , Saadi, Samer , Farah, Magdoleen H , Abusalih, Mohamed , Firwana, Mohammed , Wang, Zhen , Hassett, Leslie C. , Bancos, Irina , Murad, M. Hassan

The Journal of Clinical Endocrinology & Metabolism | May 15, 2025 | Volume: 110 | Issue: 9 | Pages: e2833-e2844

10.1210/clinem/dgaf290 | PMID 40658500 Get It

Abstract Context Primary aldosteronism (PA) is a leading endocrine cause of secondary hypertension. Objective To support the development of the Endocrine Society Clinical Practice Guideline on managing PA. Data Source MEDLINE, Embase, Scopus, and others were searched on October 4, 2024. Study Selection Studies were selected by pairs of independent reviewers. Data Extraction Data were extracted and appraised by pairs of independent reviewers. Data Synthesis We included 95 studies (7 randomized trials and 88 observational studies). We did not identify trials that evaluated the outcomes of PA screening. One observational study suggested that screening was associated with higher rates of using PA-specific medical therapies and better blood pressure control. Patients managed with adrenal venous sampling (vs computed tomography alone) may have a better post-adrenalectomy biochemical cure rate, but with an increased risk of adrenal hemorrhage. Two small observational studies suggested that PA-specific medical or surgical therapy was likely associated with better blood pressure control than nonspecific therapy. Small randomized trials suggested that surgical therapy may be associated with better blood pressure control than medical therapy, with a lower number and dosage of antihypertensive medications. Compared to eplerenone, spironolactone may be associated with better control of hypokalemia and a lower number and dosage of antihypertensive agents. Unsuppressed plasma renin activity was associated with better control of hypokalemia, while suppression was associated with higher risk of mortality, atrial fibrillation, and stroke (very low certainty). Conclusion This systematic review addresses various aspects of managing PA and will support the development of the Endocrine Society guidelines.
Genotype–phenotype correlations and clinical outcomes of genetic TRPC6 podocytopathies
McAnallen, Susan, Elhassan, Elhussein A. , Stoneman, Sinéad, Hogan, Marie C. , Hoefele, Julia , Clince, Michelle , Jorge, Sofía , Calado, Joaquim , Colliou, Éloïse, Tellier, Stéphanie , Cornet, Joséphine, Fallois, Jonathan de , Dossier, Claire , Loberti, Lorenzo , Godefroid, Nathalie, Astrid, Dubrasquet, Kálmán, Tory, Dolan, Niamh, Alawi, B, Sweeney, Clodagh, Stack, Maria, Awan, Atif , Hui, Ng Kar, Harris, Trudie , Haeberle, Stefanie , Schäfer, Franz, McCann, Emma, Vairo, Filippo , Hogan, Marie C , Hoefele, Julia , Titan, Silvia M , Renieri, Alessandra , Pinto, Anna Maria , Quintana, Luis F , Becherucci, Francesca , Biros, Erik , Kidd, Kendrah , Mallett, Andrew J , Vairo, Filippo Pinto e , Mekraksakit, Poemlarp , Titan, Silvia , Decramer, Stéphane , Francisco, Telma , Servais, Aude , Fenoglio, Roberta , Renieri, Alessandra , Daga, Sergio , Fila, Marc , Quintana, Luís F. , Godefroid, Nathalie, Kálmán, Tory, Dolan, Niamh, Alawi, Bushra Al, Riordan, Michael , McCarthy, Hugh J. , Bleyer, Anthony J. , Sayer, John A , Benson, Katherine Angela , Conlon, Peter J.

Nephrology Dialysis Transplantation | May 15, 2025 | Volume: 41 | Issue: 1 | Pages: 79-91

10.1093/ndt/gfaf086 | PMID 40388293 Get It

ABSTRACT Background and hypothesis Podocytopathy associated with likely pathogenic/pathogenic variants of Transient receptor potential cation channel subfamily C member 6 (TRPC6) (TRPC6-AP) has been recognized for about 20 years. As a result of its rarity however, the spectrum of clinical phenotypes and genotype–phenotype correlation of TRPC6-AP remains poorly understood. Here, we characterized clinical, histological and genetic correlates of familial and sporadic patients with TRPC6-AP. Methods In this multicentre observational study, an online questionnaire followed by a systematic literature review was performed to create a cohort with comprehensive data on genetic and clinical outcomes [age of onset, clinical presentation, treatment response, kidney biopsy findings and progression to kidney failure (KF)]. Logistic regression, Cox proportional hazards model and Kaplan–Meier analyses investigated the associations between genetic variants and disease progression. Results Among 87 families (96 familial and 45 sporadic cases), 31 distinct missense TRPC6 variants (including 2 novel) were identified, with c.2683C>T p.(Arg895Cys) and c.523C>T p.(Arg175Trp) the commonest variants. Proteinuric kidney disease/nephrotic syndrome was the most common clinical presentation (83.7%), while focal segmental glomerulosclerosis was the most common histological finding (89.4%). By 33 (interquartile range 17–40) years, 48.9% (69/141) of patients had progressed to KF. Sporadic TRPC6-AP demonstrated an earlier progression to KF than familial cases (P = .001) and were more likely to present with nephrotic syndrome [odds ratio 4.34 (1.85–10.15); P = .001]. Gain-of-function TRPC6 variants were more frequent in familial than sporadic TRPC6-AP (70.8% vs 44.4%; P = .004). Compared with patients with other TRPC6 variants, patients with TRPC6 p.R175W and p.R895C variants progressed to KF earlier [median kidney survival of 21 years, hazard ratio 2.985 (95% confidence interval 1.40–5.79); and 38 years, hazard ratio 1.65 (95% confidence interval 1.01–2.81), respectively, log-rank P = .005]. Conclusion Our study shows unique clinical and genetic correlations of TRPC6-AP, which may enable personalized care and promising novel therapies.
Osteochondral Allograft and Autograft Transplant for Femoral Head Defects: A Multicenter Study
Clark, Sean C. , Nagelli, Christopher V. , DeNovio, Anthony , Hevesi, Mario , Krych, Aaron J. , Economopoulos, Kostas J. , Hevesi, Mario , Krych, Aaron J , Sierra, Rafael J.

The American Journal of Sports Medicine | May 15, 2025 | Volume: 53 | Issue: 8 | Pages: 1832-1840

10.1177/03635465251338062 | PMID 40371749 Get It

Background: Osteochondral allograft transplant and autograft transplant for femoral head defects have emerged as promising treatments for concomitant cartilage and subchondral bone injuries in young patients. Purpose: To evaluate the clinical and radiological outcomes of patients who underwent osteochondral allograft or autograft transplant for femoral head defects and identify any risk factors that may lead to conversion to total hip arthroplasty (THA). Study Design: Case series; Level of evidence, 4. Methods: All patients who underwent osteochondral allograft or autograft transplant for femoral head defects across 2 institutions were analyzed. Clinical outcomes were assessed at final follow-up with the modified Harris Hip Score (mHHS), Hip Outcome Score–Activities of Daily Living (HOS-ADL), Hip Outcome Score–Sport-Specific Subscale (HOS-SSS), and International Hip Outcome Tool (iHOT-12). Complications and reoperations were recorded. Patients were assessed radiographically preoperatively and at final follow-up for osteoarthritis using Tönnis grading. Results: A total of 27 patients were included in this study (19 osteochondral allograft transplant, 8 osteochondral autograft transplant). The mean follow-up for the allograft and autograft cohorts was 2.8 and 9.5 years, respectively. The mean defect size for patients who underwent allograft and autograft transplant was 2.8 × 2.1 cm and 1.6 × 1.0 cm, respectively. The mean mHHS, HOS-ADL, HOS-SSS, and iHOT-12 for the allograft cohort were 86.7, 92.8, 81.4, and 79.0, respectively, and for the autograft cohort were 87.6, 92.7, 83.1, and 82.0, respectively. No significant difference in outcomes was noted for patients who underwent femoral head allograft versus nonorthotopic femoral condyle allograft transplant. For the allograft cohort, 4 patients (21.1%) underwent conversion to THA at a mean of 1.9 years. Of the remaining 15 allograft patients, only 1 patient (6.7%) had radiographic osteoarthritis progression. None of the patients in the autograft cohort underwent conversion to THA. Conclusion: Osteochondral allograft and autograft transplant for femoral head defects demonstrated overall favorable clinical outcomes and rates of conversion to THA. Additionally, nonorthotopic femoral condyle allografts demonstrated similar outcomes to femoral head allografts. Both osteochondral allograft and autograft transplant should be considered for patients with focal femoral head defects.
Expert Strategies: Skull Base Reconstruction—Global Perspectives, Insights, and Algorithms through a Mixed Methods Approach
Talati, Vidit , Patel, Jagatkumar A. , Nguyen, Theodore V. , Pang, Jonathan C. , Liu, Lauren , Craig, John R. , Papagiannopoulos, Peter , Phillips, Katie M. , Tajudeen, Bobby A. , Adappa, Nithin D. , Sedaghat, Ahmad R. , Anand, Vijay K. , Batra, Pete S., Bergsneider, Marvin, Casiano, Roy R. , Cavallo, Luigi Maria , Cohen, Marc A. , Eloy, Jean Anderson , Evans, James J., Fernandez‐Miranda, Juan C. , Ferrari, Marco , Froelich, Sébastien , Gardner, Paul A. , Gray, Stacey T. , Hanna, Ehab Y., Harvey, Richard J. , Hong, Sang Duk , Hwang, Peter H. , Kong, Doo‐Sik , Lan, Ming‐Ying , Lee, John Y. K. , Levine, Corinna G. , Meço, Cem , Nicolai, Piero, Nyquist, Gurston , Omura, Kazuhiro , Patel, Zara M. , Celda, María Peris, Prevedello, Danny M., Rabinowitz, Mindy, Raza, Shaan M., Sargi, Zoukaa , Schlosser, Rodney J. , Schwartz, Theodore H. , Sindwani, Raj , Stamm, Aldo Cassol , Thorp, Brian D. , Wang, Marilene B. , Wang, Wei‐Hsin , Witterick, Ian , Won, Tae‐Bin , Woodworth, Bradford A. , Wormald, Peter‐John, Zada, Gabriel , Su, Shirley Y. , Kuan, Edward C , Talati, Vidit , Nguyen, Theodore V , Pang, Jonathan C , Craig, John R , Sedaghat, Ahmad R , Wang, Eric W , Ferrari, Marco , Georgalas, Christos , Harvey, Richard J , Hwang, Peter H , Lan, Ming-Ying , Omura, Kazuhiro , Patel, Zara , Neto, Carlos Pinheiro, Schlosser, Rodney J , Snyderman, Carl H , Woodworth, Bradford A , Meço, Cem , Su, Shirley Y , Abiri, Arash , Goshtasbi, Khodayar , Adappa, Nithin D. , Bergsneider, Marvin , Bernal‐Sprekelsen, Manuel , Bleier, Benjamin S. , Cappabianca, Paolo , Carrau, Ricardo L. , Castelnuovo, Paolo , Dallan, Iacopo , El‐Sayed, Ivan H. , Hanna, Ehab Y., Kelly, Daniel F. , Liu, James K. , Locatelli, Davide , McKean, Erin L. , Nicolai, Piero , Passeri, Thibault , Pinheiro‐Neto, Carlos , Prevedello, Danny M., Recinos, Pablo F. , Rosen, Marc R , Turri‐Zanoni, Mario , Wormald, Peter‐John

International Forum of Allergy & Rhinology | May 15, 2025 | Volume: 15 | Issue: 10 | Pages: 1032-1069

10.1002/alr.23596 | PMID 40371737 Get It

ABSTRACT Objective There is limited consensus on endoscopic skull base surgery (ESBS) reconstruction principles. This study aims to generate comprehensive themes regarding ESBS reconstruction by pooling the experiences of ESBS experts, with comparison to a literature review of current published evidence. Methods Structured qualitative interviews of ESBS experts regarding postoperative management and reconstruction of various defect locations were conducted. Results A total of 68 experts comprising 40 academic teams across 13 countries with an average of 18 years of ESBS experience were included. We propose 10 stepwise algorithms for common skull base reconstruction scenarios based on these expert interviews. When available, the nasoseptal flap is used for all high_flow cerebrospinal leak defects. Multilayered reconstruction is favored at all anatomical subsites with increasing number of layers for increasing defect size and complexity. Heterogeneity exists in terms of inlay technique and materials, free grafting versus various pedicled flap options for low‐flow defects or in the absence of a nasal septum, nasal packing, tissue sealant, lumbar drain use, and postoperative management. Commonalities and discrepancies between experts were summarized. Conclusion Skull base reconstruction and post‐ESBS management is highly complex with a wide variety of practice patterns and expert strategies. Further research of higher quality evidence is warranted to identify optimal management patterns, though the current work aims to inform surgeons on these controversial areas by drawing from numerous experiences.
Characterizing Disease Severity, Comorbidities, and Treatment Plans in Pediatric Hidradenitis Suppurativa Patients With and Without Obesity: A Cohort and Cross‐Sectional Analysis
Numani, Asfia , Ziebart, Rachel, Aghazadeh, Nessa , Davis, Dawn Marie R. , Davis, Dawn M R , Numani, Asfia , Aghazadeh Mohandesi, Nessa , Todd, Austin W. , Alavi, Afsáneh

Pediatric Dermatology | May 15, 2025 | Volume: 42 | Issue: 4 | Pages: 773-778

10.1111/pde.15983 | PMID 40371736 Get It

ABSTRACTBackgroundHidradenitis suppurativa (HS) is a chronic inflammatory condition. While obesity is linked to increased HS severity in adults, data on its impact in pediatric HS remain limited. This study investigates the relationships between obesity, HS severity, HS‐related comorbidities, and therapeutic management in pediatric patients.MethodsThis is a retrospective cohort analysis on patients diagnosed with HS before 18 years of age. Data were collected on disease severity, comorbidity development, and treatments. Trends were compared between HS patients with and without obesity and with healthy controls for comorbidity development.ResultsThere was no difference in disease severity using Hurley staging between patients with and without obesity (p = 0.679). Patients with obesity were more likely to be prescribed biologics (p = 0.012), but not other treatments. The risk of developing dyslipidemia, anxiety, depression, and thyroid disease was elevated in pediatric HS patients, even after controlling for BMI (p < 0.001).ConclusionsIn this study, obesity was not associated with HS disease severity in children. However, children with obesity were more likely to be prescribed biologics. HS may independently increase the risk of dyslipidemia, anxiety, depression, and thyroid disease.
Three approaches to determining clinically meaningful benefit on the Cohen‐Mansfield Agitation Inventory in dementia clinical trials for agitation
Liu, Kathy , Ivenso, Chineze , Rapaport, Penny , Reeves, Suzanne , Schneider, Lon S. , Group, Agitation MCID Study, Howard, Robert, Howard, Robert , Liu, Kathy Y , Reeves, Suzanne , Howard, Rebecca, Banerjee, Sube , Lapid, Maria I. , Group, Agitation MCID Study, Howard, Robert

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 15, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70099 | PMID 40376142 Get It

Abstract INTRODUCTION There is a need to understand the clinical meaningfulness of symptom score changes in treatment trials of dementia‐related agitation. We estimated minimal clinically important differences (MCIDs) for commonly employed agitation scales and contextualized their clinical application. METHODS We employed anchor‐ and distribution‐based approaches to determine changes in scores corresponding to minimal symptom improvement. An opinion‐based approach assessed expert clinicians’ agreement on the meaningfulness of score changes through three clinical vignettes. RESULTS Minimal symptom improvement for Cohen‐Mansfield Agitation Inventory total score ranged from −4 (over <1 month) to −11 (over 1 to 3 months) points. Greater symptom severity correlated with higher MCID estimates. The clinical importance of score changes was influenced by treatment duration, pharmacological side effects, and impacts on caregiver distress/time resources. DISCUSSION The clinical meaningfulness of agitation scale MCIDs is influenced by trial‐specific and clinical factors. Shorter trial durations and measuring caregiver distress/time resources enhance the clinical interpretation of agitation treatment outcomes. Highlights For the CMAI total score, the MCID was −4 points over shorter time scales and −11 points for longer time scales. Worse agitation severity was associated with higher MCID estimates. There was high expert consensus that a noticeable treatment benefit was not worthwhile if it occurred after 12 weeks or had no impact on caregiver/staff distress/time resources.
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Michieli, Laura De , Guida, Gianluigi , Saturi, Giulia , Sena, Guido De , Capovilla, Teresa Maria , Cantone, Anna , Cianca, Alessandro , Lupi, Alessandro , Porcari, Aldostefano , Vergaro, Giuseppe , Albertini, Riccardo, Serenelli, Matteo , Merlo, Marco , Longhi, Simone , Marra, Martina Perazzolo , Iliceto, Sabino , Jaffe, Allan S. , Milani, Paolo , De Michieli, Laura , Guida, Gianluigi , Saturi, Giulia , Sena, Giuseppe , Capovilla, Teresa Maria , Cantone, Anna , Porcari, Aldostefano , Tini, Giacomo , Vergaro, Giuseppe , Cappelli, Francesco , Bianco, Matteo , Mussinelli, Roberta , Musumeci, Beatrice , Perlini, Stefano , Merlo, Marco , Longhi, Simone , Sinagra, Gianfranco , Perazzolo Marra, Martina , Iliceto, Sabino , Jaffe, Allan S. , Palladini, Giovanni , Cipriani, Alberto , Milani, Paolo , Sinigiani, Giulio , Bianco, Matteo , Mussinelli, Roberta , Perlini, Stefano , Palladini, Giovanni

Circulation: Heart Failure | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.125.012816 | PMID 40371473 Get It

BACKGROUND: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. The aims of this study were: first, to assess the prognostic performance of hs-cTnI measured with different assays in patients with wild-type transthyretin amyloid cardiomyopathy and, second, to identify assay-specific hs-cTnI thresholds for prognosis that could be integrated into staging systems for risk stratification. METHODS: Observational multicenter study of stable wild-type transthyretin amyloid cardiomyopathy patients from different cohorts using the Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) and the Siemens Centaur XPT hs-cTnI assay (validation cohort). Outcome was all-cause mortality. RESULTS: In the Abbott cohort (n=136; median follow-up 22 [13–41] months; 31 [23%] deaths) and Beckman cohort (n=98; median follow-up 19 [12–28] months; 16 [16%] deaths), natural log-transformed hs-cTnI was an independent predictor of mortality (age- and sex-adjusted hazard ratio, 1.62 [95% CI, 1.11–2.35]; P =0.012 and 2.47 [95% CI, 1.48–4.14]; P <0.001, respectively). The best hs-cTnI threshold for 18-month mortality of the combined Abbott/Beckman cohorts (n=234) was 81 ng/L, rounded to 80 ng/L for simplicity of clinical use. A 2-variable staging system (based on the Mayo Clinic system) using hs-cTnI (>80 ng/L) and NPs (natriuretic peptides; NT-proBNP [N-terminal pro-B-type natriuretic peptide] >3000 ng/L or BNP [B-type natriuretic peptide] >250 ng/L) identified 3 groups with progressively worse prognosis. The staging system (using hs-cTnI >80 ng/L and NT-proBNP>3000 ng/L) was then applied to an independent cohort evaluated with the hs-cTnI Siemens assay (n=345, median follow-up 32 [24-42] months, 119 [34%] deaths). The significant differences between the groups were maintained. CONCLUSIONS: In patients with wild-type transthyretin amyloid cardiomyopathy, hs-cTnI is a strong and independent predictor of mortality. A threshold of hs-cTnI of 80 ng/L for these 3 assays provides effective risk stratification alone and in a staging system with NP.
Optimal Target of Activated Clotting Time During PCI and Outcomes: The OPTIMAL-ACT Trial
Gharacholou, S. Michael , Thomas, Colleen S. , Hodge, David O. , Sabbagh, Abdallah El , Lane, Gary E. , Pollak, Peter , Pillai, Dilip, Johns, Gretchen S., Donato, Leslie J. , Singh, Mandeep , El Sabbagh, Abdallah , Pollak, Peter M , Pillai, Dilip P, Johns, Gretchen, Donato, Leslie

Circulation: Cardiovascular Interventions | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.015291 | PMID 40371483 Get It

Quantification of Initial Symptom Relief Following Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules
Atwell, Thomas D. , Schmitz, John J. , Ryder, Mabel , Roll, Rebecca J, Castro, M. Regina , Kassmeyer, Blake A., Kurup, A. Nicholas , Ryder, Mabel , Stan, Marius N.

Ultrasound Quarterly | May 15, 2025 | Volume: 41 | Issue: 2 | Pages: No page available

10.1097/ruq.0000000000000716 | PMID 40369808 Get It

Abstract The use of radiofrequency ablation (RFA) of benign, symptomatic thyroid nodules is growing in clinical practice. Objective outcomes of symptom relief are needed to support the use of this treatment. Thus, a previously established thyroid nodule symptom scoring system was prospectively administered to patients prior to RFA of symptomatic thyroid nodules and then at 1, 3, 6, and 12 months following ablation. A total of 38 patients of mean age 57 years were treated with RFA between August 2022 and January 2024 and completed at least 1 follow-up survey. Five of these patients underwent simultaneous ablation of 2 thyroid nodules; the remainder had a single nodule treated. Mean modified symptom score prior to RFA was 3.5 (SD 1.6) with higher scores correlating with increasing baseline nodule volume (R = 0.46, P = 0.0038). Patient symptom scores decreased at the first 1-month survey (mean 1.2; SD 1.3) and 3-month survey (mean 0.9; SD 1.3) with durable response in those patients with more extended follow-up. In those patients with imaging follow-up, decreasing nodule size was shown to correlate with decreasing symptoms. The early results of this study show that RFA of benign, symptomatic thyroid nodules results in quantifiable symptom relief within 3 months of treatment. Such objective measures of symptom relief may be used to measure long-term durability of treatment.